GE HealthCare is correcting certain Carestation devices due to the risk that they may not provide effective ventilation when used in volume control ventilation mode, according to a medical device recall notice from the US Food and Drug Administration (FDA). 

In these systems, effective ventilation can be achieved in pressure control ventilation or pressure control ventilation volume guarantee modes—or with manual ventilation. 

If this issue occurs, GE HealthCare notes that it will be apparent to the Carestation user through observation and multiple alarms. The inflated bellows, visible through transparent glass, will stop moving, and an audible alarm and visual “Unable to Drive Bellows” message will alert the user. Additional alarms, including apnea, EtCO2 low, MVexp low, RR low, and TVexp low, will also alert the user to inadequate ventilation.

The use of the affected product may cause serious adverse health consequences, including failure of ventilation resulting in hypoxia and death.  

A spokesperson with GE HealthCare says the company is working with hospitals to address the issue and ensure continued device use. “Patient safety is our top priority. After identifying a potential issue with certain Carestation anesthesia delivery systems that may impact effective ventilation in one specific mode of ventilation, we are providing hospitals with instructions to follow to continue use of their devices,” the spokesperson says. “We will be correcting all impacted systems. There have been no reports of patient injury as a result of this potential issue.”

Intended use of the Carestation is to provide monitored anesthesia care, general inhalation anesthesia, and/or ventilatory support to a wide range of patients (neonatal, pediatric, and adult). The anesthesia systems are suitable for use in a patient environment, such as hospitals, surgical centers, or clinics by a clinician qualified in the administration of general anesthesia.

This recall involves correcting certain devices and does not involve removing them from where they are used or sold. The FDA has identified this recall as the most serious type.

The affected product names are Carestation 620/650/650c and 750/750c Anesthesia Systems. 

Customers in the US with questions about this recall should contact GE HealthCare Service at 1-800-437-1171.  

ID 249615353 © Thanee Hengpattanapong | Dreamstime.com

Related Read:

GE HealthCare is showcasing its latest molecular imaging technologies for cardiology—including Flyrcado (flurpiridaz F 18)—at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in New Orleans. The company’s portfolio, which includes imaging systems, radiopharmaceuticals, and analysis software, is aimed at improving the diagnosis and monitoring of cardiovascular disease (CVD), including coronary artery disease (CAD).

Central to this effort is GE HealthCare’s Flyrcado (flurpiridaz F 18) injection, a PET myocardial perfusion imaging (MPI) agent developed for use in patients with known or suspected CAD. Approved for use in the US, Flyrcado provides clinicians with a new option for cardiac PET imaging, offering higher diagnostic efficacy than SPECT MPI—the more commonly used modality in nuclear cardiology today.

“Flyrcado represents one of the most significant advancements in nuclear cardiology in decades,” says Marcelo Fernando DiCarli, MD, chief of the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Executive Director, Cardiovascular Imaging Program, Departments of Radiology and Medicine, Brigham and Women’s Hospital, in a release. “For the first time in nearly 20 years, we have a new PET myocardial perfusion tracer that brings latest imaging technology within reach for patients across the US. The image quality is exceptional, and its use has the potential to reduce unnecessary invasive procedures by improving diagnostic confidence.”

Coverage Expands for Flyrcado F 18

Flyrcado was recently launched in select US markets. As of April 1, the agent received CMS pass-through status and a specific HCPCS billing code. GE HealthCare reports that it is now covered by all seven Medicare Administrative Contractors and included in updated commercial cardiac PET coverage policies affecting more than half of the US commercially insured population. Additional policy updates are expected later in the year. The company has also introduced a Flyrcado Support Center to assist with benefits investigation, coding, and claims submissions.

Flyrcado is compatible with multiple PET/CT systems, including Omni Legend, which GE HealthCare says supports flexible cardiac PET workflows. The system is designed to accommodate a range of tracers and is part of a scalable platform developed to meet demands for shorter scan times and lower radiation doses.

“With coverage now in place for all traditional Medicare beneficiaries, along with updated PET coverage policies in place for more than half of the nation’s commercially insured beneficiaries, millions of Americans—many at risk for or living with coronary artery disease, the leading cause of death in the US—will have greater access to this innovative technology,” says Eric Ruedinger, vice president and general manager of GE HealthCare’s pharmaceutical diagnostics division for the US and Canada, in a release. 

SPECT/CT and Software Spotlighted

Additional cardiac imaging technologies on display include:

• StarGuide and Aurora: SPECT/CT systems designed to support cardiac diagnostics by capturing gamma rays from injected tracers. Both systems are optimized for image quality and scan efficiency, allowing clinicians to assess both physiological and structural cardiac conditions.
• MIM Software: Provides tools for multimodality image viewing, cardiac image fusion, and integration pathways for analysis across platforms.

These technologies aim to support early diagnosis, risk stratification, treatment planning, and monitoring in cardiology. According to GE HealthCare, molecular imaging—including PET and SPECT—offers detailed insights into biological processes, helping clinicians tailor treatment strategies and assess therapy response.

Photo caption: Flyrcado (flurpiridaz F 18)

Photo credit: GE HealthCare

Related Reads:

At the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is highlighting new technologies designed to support precision care in theranostics and molecular imaging. 

The company’s latest innovations include AI-powered software for tumor burden analysis, new imaging systems, and radiopharmaceutical tools intended to streamline workflows and support personalized treatment planning.

“Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,” says Erik Mittra, MD, PhD, professor of diagnostic radiology in the at Oregon Health & Science University, in a release.

Among the new releases is LesionID Pro, a version of GE HealthCare’s MIM Software featuring automated, zero-click pre-processing. The tool is designed to help physicians reduce time spent on manual lesion segmentation and image registration when analyzing whole-body tumor burden. According to GE HealthCare, the software improvements aim to support therapy response monitoring and more efficient reporting.

Molecular imaging—such as positron emission tomography (PET) and single photon emission computed tomography (SPECT)—plays a central role in theranostics by helping clinicians monitor disease and guide treatment. GE HealthCare’s updates to LesionID Pro aim to address common challenges in this space, including time-consuming manual processes. The latest version includes algorithm improvements that provide whole-body tumor volume data, which physicians can review and finalize using newly designed tools.

Theranostics-Enabling Solutions on Display

Also on display at SNMMI, as part of GE HealthCare’s portfolio of theranostics-enabling solutions, are the following innovations:

• MINItrace Magni: GE HealthCare’s newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans.
• Omni Legend: A PET/CT system designed to reduce dose by up to 40% while maintaining image quality. The system is intended to support growing demand for high-performance PET/CT in theranostic applications.
• StarGuide: A digital SPECT/CT system with 12 CZT detectors that offers 3D imaging and short scan times. The design supports lesion detection, therapy monitoring, and high patient throughput.
• Aurora: A dual-head SPECT/CT system featuring a 40 mm CT detector and dose reduction capabilities. The system is designed to provide image quality and operational efficiency in hybrid imaging environments.
• Theranostics Pathway Manager Tile: An application available through GE HealthCare’s Command Center software. The tool is designed to help clinical teams coordinate the theranostics care pathway by tracking patient readiness for therapy and consolidating information from multiple sources. Oregon Health & Science University will be an early adopter.

“Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,” says Shyam Srinivas, MD, PhD, chief of nuclear medicine, associate clinical professor, Department of Radiological Sciences, University of California, Irvine, in a release. “With tools like GE HealthCare’s Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions.”

Photo caption: LesionID Pro

Photo credit: GE HealthCare

Related Read:

By Rajani Kumar Sindavalam

Infusion pumps are essential instruments in contemporary healthcare, facilitating the precise delivery of fluids, medications, and occasionally nutrients. Ranging from simple syringe pumps to advanced smart pumps equipped with integrated drug libraries and connectivity options, these devices are crucial for patient care in various clinical environments.

Nevertheless, the growing complexity of infusion pumps, spurred by the need for improved functionality and seamless integration within the healthcare system, presents considerable challenges. Risks to patient safety arise from medication errors, usability concerns, cybersecurity threats, and interoperability issues, which impede the complete achievement of their clinical capabilities.

Systems engineering—an interdisciplinary domain dedicated to the design, development, and management of intricate systems throughout their lifecycles—provides a systematic framework to tackle these challenges. By embracing a comprehensive viewpoint that considers all stakeholders, system elements, and their interrelations, the medical technology sector can facilitate the creation of safer, more user-centric, and genuinely intelligent infusion pumps.

Challenges in Infusion Pump Development

Developing infusion pumps is complex and necessitates a robust systems engineering methodology. These challenges include both technical and clinical dimensions, each with direct implications for patient safety and regulatory compliance:

• Safety-Critical Nature: Infusion pumps directly impact patient health. A malfunction—such as the over- or under-administration of essential medications—can have serious or life-threatening consequences. Safety must remain the top priority throughout every stage of development.
• Stringent Regulatory Requirements: Medical devices, including infusion pumps, are subject to rigorous oversight from regulatory bodies such as the US Food and Drug Administration and European Medicines Agency. Compliance demands extensive documentation, testing, and validation—core elements of systems engineering that ensure quality and accountability.
• Human Factors and Usability: These devices are often used in fast-paced clinical environments. Poorly designed interfaces, unclear alarms, or complex workflows increase the likelihood of error. Integrating human factors engineering into the design process helps ensure devices are intuitive and safe to use.
• Software Complexity: Modern pumps rely heavily on embedded software for drug delivery, alarms, and connectivity. As functionality expands, so does the potential for defects. Addressing this complexity requires disciplined software development practices.
• Interoperability and Data Integration: Infusion pumps must integrate with systems like EHRs and pharmacy platforms. Achieving seamless, secure interoperability requires careful design and validation to maintain data integrity.
• Cybersecurity Threats: Network-connected pumps are vulnerable to cyber threats that could impact functionality or expose patient data. Embedding robust security protocols from the start is essential.
• Lifecycle Management: Systems engineering must span the entire product lifecycle, including manufacturing, maintenance, and disposal. Ongoing oversight ensures continued performance and safety.

Putting Systems Engineering to Work

A systematic application of systems engineering principles helps navigate these challenges. The process begins with stakeholder analysis and requirements elicitation—identifying the needs of patients, clinicians, pharmacists, engineers, and regulators. For example, insights from ICU nurses can inform interface design and alarm functionality.

Functional analysis and system architecture design follow, breaking the pump into components such as fluid delivery, occlusion detection, user interface, and data transmission. A well-structured architecture promotes modularity, testability, and long-term maintainability.

Risk management is central. Structured tools like Failure Modes and Effects Analysis and hazard analysis help identify and mitigate risks early. For instance, analyzing potential failure points in the pump mechanism can support the development of more responsive occlusion detection.

Human factors engineering and usability testing ensure that the pump is intuitive and minimizes user error. Simulated clinical testing with representative users helps refine visual and auditory alarms and workflow steps.

Given the pump’s software dependence, software systems engineering is vital. This includes managing requirements, developing architecture, performing rigorous testing, and ensuring cybersecurity. Following standards like IEC 62304 and using secure coding practices reduces risk.

Verification and validation—from unit tests to system-level evaluations and clinical trials—confirm the device meets specifications and performs safely.

Configuration management and traceability maintain oversight of documentation, components, and changes across the lifecycle. Traceability matrices linking requirements to test cases and risk controls reinforce a disciplined development process.

Finally, post-market surveillance ensures continued device safety. Monitoring field performance, collecting feedback, and managing recalls allow for continuous improvement based on real-world data.

Powering the Next Generation of Smart Infusion Pumps

Emerging technologies such as artificial intelligence (AI), machine learning (ML), and improved connectivity are propelling the development of smart infusion pumps. Systems engineering ensures these innovations are integrated safely and effectively.

Predictive analytics powered by AI/ML can identify potential issues like occlusions or low medication levels before they occur. Systems engineering defines the requirements for these algorithms, supporting accuracy and safety.

Connectivity and interoperability are essential. Pumps must reliably exchange data with EHRs, pharmacy systems, and other devices. Engineering principles guide the development of secure interfaces and resilient communication protocols.

Looking ahead, real-time patient data may be used to adjust infusion rates dynamically. Developing these adaptive control features requires validated algorithms and integration into reliable feedback systems.

What’s Next—and What’s Needed

To support the continued evolution of infusion pumps, manufacturers should embrace key best practices. These include early and ongoing stakeholder engagement to ensure development is aligned with real-world clinical needs. Involving users from the outset helps avoid costly redesigns later.

Additionally, comprehensive risk management should be embedded across all phases of development as proactively addressing safety risks leads to safer, more robust devices.

Human-centered design, including attention to usability and clinical workflows, helps ensure safe and intuitive operation in demanding settings, while interoperability remains essential. Standardized communication protocols simplify integration with other health IT systems.

Software and cybersecurity practices must evolve with the technology. Adhering to development standards and adopting secure design principles will reduce vulnerabilities.

Additionally, post-market surveillance using real-world data helps identify issues and guide iterative improvements, and ethical considerations around AI and ML should be addressed early. Transparency, accountability, and bias mitigation are critical for responsible integration.

Finally, industry-wide collaboration can accelerate progress. Sharing best practices, tools, and lessons learned contributes to safer, smarter infusion technology.

The Path Forward

Advancing smart infusion pumps requires a comprehensive approach grounded in systems thinking. By applying engineering principles across the entire lifecycle—from early design to post-market surveillance—developers can build safer, more reliable devices.

As the medtech industry continues to innovate, systems engineering provides the foundation for addressing complexity and unlocking the full potential of infusion pump technology to improve patient outcomes. 

About the Author: Rajani Kumar Sindavalam is a senior technical manager and medical device leader at HCLTech. He has more than 19 years of experience supporting the development of medical technologies, including infusion pumps, bedside monitors, dialysis cyclers, and nerve stimulators.

ID 324812795 | Abstract Network © janisphotostories | Dreamstime.com

By Joseph Gucciardi, MS, CCE

At the 2025 AAMI eXchange in New Orleans, I co-presented a session titled “From Reactive to Proactive: Enhancing Medical Device Safety in the CMMS,” a topic that strikes a nerve with HTM professionals facing increased expectations—from faster repairs and tighter compliance to a stronger role in patient safety. 

Our goal was to show how the CMMS can become more than a logbook for work orders. With the right workflow design, it can be a proactive tool for managing clinical risk.

Why Now?

Healthcare organizations are under mounting pressure: aging medical devices, staffing shortages, cybersecurity threats, and increased regulatory oversight. HTM teams are expected to do more with less—and ensure that medical equipment is not only functional but also safe, documented, and ready to support care.

Yet most CMMS tools still rely on basic intake fields and reactive workflows. Tickets often lack context. Safety issues go unnoticed until audits—or worse, until patient care is delayed. HTM teams know the data is there, but they haven’t had the tools to act on it.

A New Approach to CMMS Design

The session introduced a patient safety–oriented redesign of CMMS workflows. While the examples are based on recent implementation experiences, the strategies discussed aren’t vendor-specific; they’re grounded in concepts any HTM team can begin applying.

We focus on five key areas:

1. Structured Intake: Forms and digital tools can be designed to capture clinical impact upfront. Questions like “Was patient care delayed?” or “Is the device currently in use?” help flag potential safety risks at the point of intake.
2. Risk-Based Triage and Assignment: Instead of triaging by ticket order, workflows can use device attributes, service history, and clinical location to assign and escalate based on risk. Predictive models and rules-based logic can enhance this approach.
3. Dashboards that Surface Safety Issues: Dashboards can highlight unresolved work on high-risk devices, show Service Level Agreement breaches, and spot recurring safety-related patterns. These aren’t just metrics—they’re conversation starters for compliance reviews, department meetings, and capital planning.
4. Integrations with Other Systems: Tying the CMMS to cybersecurity tools, incident reporting platforms, and recall management systems closes the loop. When device-related risks are flagged in multiple systems, HTM can respond faster and document the full picture.
5. Patient Safety as a Workflow Outcome: Medical device safety isn’t just about preventing downtime. It’s about embedding safety logic into how work orders are created, prioritized, routed, and resolved.

Practical Takeaways for Any HTM Team

Any HTM department can begin shifting its CMMS toward safety outcomes by: 

• Adding structured intake questions related to patient care impact 
• Using existing asset fields (location, criticality) to guide routing 
• Creating dashboards that highlight unresolved issues tied to high-risk devices 
• Collaborating with risk management, cybersecurity, and informatics teams to share data

These small changes lay the groundwork for a more proactive CMMS—one that not only tracks what’s broken but also helps prevent the next issue from happening at all.

The Road Ahead

As HTM takes on a larger role in clinical safety, our systems must evolve with us. Whether you’re customizing an existing CMMS or exploring new platforms, think beyond the next PM schedule. Ask how your data, workflows, and reporting can help your team surface and act on safety risks—before they reach the bedside.

Author Bio: Joseph Gucciardi, MS, CCE, is a business process consultant with Optimum Healthcare IT and a certified clinical engineer. He previously served as a senior regional clinical engineer with the US Department of Veterans Affairs.

Disclosures: The author consults on healthcare workflow design and implementation. This article reflects general principles and does not promote any specific product or platform.

ID 113077722 © Dreammasterphotographer | Dreamstime.com

Related Read:

Creo Medical has received clearance from the US Food and Drug Administration (FDA) for its SpydrBlade Flex device, completing the company’s regulatory approvals for its suite of advanced energy gastrointestinal (GI) tools.

SpydrBlade Flex is a multi-modal endoscopic device that provides both cutting and coagulation functions—features traditionally found in laparoscopic surgery—via a flexible endoscope. It is designed for a range of therapeutic endoscopy procedures and combines multiple functionalities in a single tool.

Following its commercial launch in Europe in March 2025, SpydrBlade Flex has been used in procedures including:

• Zenker’s Peroral Endoscopic Myotomy 
• Colonic ESD
• Oesophageal ESD
• POEM
• F-POEM

With FDA clearance secured, Creo plans to begin commercial rollout in the United States through its direct sales force and clinical partnerships.

The clearance comes shortly after the American Medical Association’s May 2025 decision to introduce reimbursement codes for endoscopic submucosal dissection, establishing a reimbursement pathway that may support broader adoption of tools like SpydrBlade Flex.

The device is part of Creo’s lineup of advanced energy GI products, which also includes Speedboat UltraSlim, Speedboat Notch, and MicroBlate Fine.

“FDA clearance for SpydrBladeTM Flex confirms the strength and novelty of our GI product portfolio. The device has overcome significant design challenges, with unique intellectual property that sets it apart in the market,” says Craig Gulliford, chief executive officer of Creo Medical, in a press release.

Photo caption: SpyderBlade Flex

Photo credit: Creo Medical

Related Read:

Agiliti announced the launch of its new NP Line of stretcher support surfaces that are clinically engineered for safer patient care.

Compatible with the majority of acute care stretchers, the three non-powered support surfaces feature a breathable, four-way stretch top cover fabric and radio frequency-welded seams for enhanced durability and less risk of microbial infiltration.

“Stretcher pads are among the most used pieces of medical equipment in emergency and perioperative departments and subject to rapid wear and tear,” says Tim McCarty, general manager of beds and therapeutic support surfaces at Agiliti, in a release. “We designed the NP Line of stretcher support surfaces with features to help improve patient comfort, reduce the risk of contamination, and offer customers a highly durable surface option in their highest-volume environments.”

The NP Line includes the following products:

• NP Adjust ST, which features self-adjusting foam-filled air cells that respond to patient weight and movement. This aims to promote immersion, pressure redistribution, and comfort.
• NP Trio ST, which features three layers of foam and a sloped heel zone to support varying pressure redistribution needs.
• NP Duo ST, which features two layers of foam to provide consistent support from head to heel. The top layer of Visco foam is softer, while the firmer bottom layer adds stability and prevents bottoming out.

The NP Adjust ST and NP Trio ST also feature a CoreShield layer to protect internal components from contamination and a layer of CuPro copper- and gel-infused foam to help enhance microclimate by dissipating heat and moisture.

Research published by Agiliti shows that compromised surfaces pose nearly six times more risk for cross-contamination to patients. The NP Line is the latest addition to the company’s portfolio of support surface technologies designed for more advanced care across multiple clinical settings. 

Photo caption: NP Adjust ST

Photo credit: Agiliti

Related Read:

Corti has launched FactsR, a real-time agentic reasoning system designed to enhance ambient documentation during clinical consultations by reducing extraneous content and minimizing the need for post-visit edits.

The system integrates with ambient AI tools and uses a recursive, fact-first architecture to identify, validate, and structure clinical information—such as symptoms, vitals, and medications—as conversations unfold. According to Corti, early tests show that FactsR reduces AI-generated note bloat by over 65%, helping clinicians produce more concise and relevant documentation.

Unlike traditional large language models retrofitted for healthcare, FactsR is powered by Corti’s recursive fact-first reasoning loop, a purpose-built engine designed to surface, validate, and structure clinical knowledge in real time as conversations unfold. The tool is delivered as a modular API, allowing developers to embed it directly into healthcare applications.

Why a Recursive Approach Matters

Many traditional ambient documentation tools process raw transcripts through general-purpose language models after a consultation ends, often producing lengthy summaries that clinicians spend up to three hours a week correcting.

FactsR takes a different approach, from passive summarization to active reasoning. Its workflow consists of four key stages:

1. Listen and Extract in Real Time: As the consultation unfolds, FactsR continuously identifies and surfaces structured clinical “facts”—such as symptoms, vitals, medications, and social history.
2. Vet and Refine with Specialized AI: Each fact is automatically reviewed and improved through an AI-driven feedback loop. If something is unclear, the system refines it until it is accurate, consistent, and ready to use.
3. Clinician-in-the-Loop: Clinicians can review, accept, or adjust facts as they go. Early adopters report far fewer post-visit edits and rarely need to add missing information after the consultation, according to Corti. 
4. Generate EHR-Ready Notes: Once the facts are finalized, the system assembles a concise summary that’s free from long, verbose summaries or irrelevant content.

Reported benefits include:

1. Less Screen Time: Early trials show that users spend minutes, not hours, on corrections
2. Better Patient Focus: Real‑time reasoning means decisions stay in the consultation, not in hindsight.
3. Audit‑Ready Transparency: Every fact carries a timestamp, confidence score, and link back to the conversation.
4. Healthcare AI that Delivers: Reduces general-purpose AI-driven “note bloat” by 65%.

The innovation behind FactsR has been published together with evaluation results on the public benchmark Primock57 dataset. The evaluation shows that FactsR increases clinical completeness by 13%, capturing significantly more of the relevant medical information compared to traditional ambient scribes, while reducing note bloat by over 65% with a clinician in the loop.

FactsR is offered today through a consumption‑based API with enterprise‑grade HIPAA and GDPR compliance. 

ID 80884410 | Doctor Patient © Imtmphoto | Dreamstime.com

Related Read:

GE HealthCare has announced the integration of its proprietary algorithms and features with MIM Encore, a platform developed by MIM Software, aimed at improving digital imaging and streamlining clinical workflows.

The implementation offers new capabilities for healthcare providers using GE HealthCare systems and MIM software. Built using clinician feedback, MIM Encore is designed as a unified platform to support diagnostic accuracy, operational efficiency, and personalized care planning.

“In today’s rapidly evolving healthcare landscape, operational efficiency and seamless collaboration are not just goals—they’re the cornerstone to success. That’s why we aim to provide tools that can help enhance providers’ confidence in decision making and support patients in receiving personalized care,” says Jean-Luc Procaccini, president and CEO of molecular imaging and computed tomography at GE HealthCare, in a release.

Expanded Capabilities for MIM and GE HealthCare Users

MIM Encore now includes post-processing tools developed for GE HealthCare systems, aiming to support consistent image quality and reduce manual steps in nuclear medicine and cardiology workflows. The platform combines features such as automated read preparation, structured reporting, and flexible interpretation tools for PET/CT, SPECT/CT, and multi-modality fusion in one system.

According to the company, the integration is intended to support accurate diagnoses and more consistent communication across clinical teams.

“Customers are telling us that this pairing is exactly what users have been looking for. The combined solution enables streamlined, accurate reading of images, supports quantitative analysis out of the box, and helps eliminate manual entries,” says Andrew Nelson, CEO of MIM Software, a GE HealthCare company, in a release.

MIM Encore includes resolution recovery and image-enhancement features tailored to GE HealthCare scanners, with the goal of improving workflow and diagnostic consistency across specialties:

• Oncology: The platform supports configurable enhancements for SPECT imaging, including resolution recovery, attenuation and scatter correction, advanced filtering, and motion correction. It also allows for dynamic and static scan viewing, image sharing, and quantitation tools.
• Cardiology: Cardiac imaging is supported by PET and SPECT tools offering motion correction, automated quality checks, and displays intended to streamline cardiac assessments. The platform also supports key radiotracers and incorporates algorithms such as Evolution for Cardiac, developed at Johns Hopkins and the University of North Carolina.
• Neurology: MIM Encore includes tools for 3D rendering and reconstruction in neurodegenerative imaging, designed to produce consistent, high-quality images and assist in diagnosis and treatment planning.

GE HealthCare’s Effortless Workflow also integrates with MIM Encore, with features intended to simplify interface navigation, reduce manual input, and help manage increasing patient volumes.

GE HealthCare acquired MIM Software in 2024 to combine strengths in multi-modality imaging, quantitation, automation, and molecular imaging.

Photo caption: MIM Encore

Photo credit: GE HealthCare

AU10TIX, a company specializing in identity verification and fraud prevention, has expanded its product suite with the release of AnyDoc Authentication, a tool designed to detect forged, tampered, or synthetic non-ID documents that may evade traditional verification systems.

The solution uses AI, forensic forgery detection, and metadata analysis to help organizations detect document fraud, maintain regulatory compliance, and scale secure onboarding. This layer of protection supports a range of document types, including utility bills, bank statements, tax filings, business licenses, and more.

According to AU10TIX, the system runs more than 150 AI-driven forgery tests, validates embedded metadata for consistency, and processes documents within five to 20 seconds. It is format-agnostic, working with both PDFs and image files, and can classify documents in under three seconds.

Key capabilities include:

• Detection of manipulated text, synthetic content, and structural anomalies
• Cross-checking of metadata such as timestamps and issuing authority
• Support for a range of document types
• Real-time decision-making and document classification

“Effective fraud prevention demands more than identity verification; it is built on ensuring the authenticity of every supporting document,” said Yair Tal, CEO of AU10TIX, in a statement.

AnyDoc Authentication is designed to align with KYC, KYB, and AML regulatory frameworks. It incorporates third-party data verification to reduce false positives and detect synthetic or deepfake document attempts. Optimized for high-risk, high-volume sectors, AnyDoc Authentication is suited for multiple industries, including healthcare where it can assist in authenticating insurance documents, prescriptions, and provider credentials. 

AnyDoc Authentication is now available to businesses seeking to enhance fraud detection and regulatory compliance.

ID 212388480 © Nicoelnino | Dreamstime.com